COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Evaluation of Nanomedicine Drug Release and Pharmacokinetics

The NCL has two Technical Services to measure drug release from nanomedicines—ideal for assessing bioequivalence of complex drugs. These assays are available as a service to nanomedicine developers, apart from NCL’s Assay Cascade application process.

The two assays utilize the Stable Isotope Tracer Ultrafiltration Assay (SITUA), and include:

  1. In vitro drug release in human plasma
  2. A pharmacokinetic study in rats

Evaluation of Nanomedicine Drug Release and Pharmacokinetics

The assay uses a stable isotopically labeled version of the drug and a simple ultrafiltration technique, allowing for easy measurement of plasma protein bound, unencapsulated and encapsulated nanomedicine fractions. (J Control Release, 2015, 220(Pt A), 169-174.)

To learn more about the assay, watch this video or download a printable brochure. You can also find more information on NCL's Technical Services page.

Have questions or interested in the service? Contact the NCL team at ncl@mail.nih.gov. We'd be happy to have a one-on-one call with your team to discuss the specifics of your formulation and how this assay might be applied.